Golf wrote "This Phase III looks like BoM2, but only for a covid-infected population."

Koo wrote "Golf it would be nice if Bear weighs in to see if he agrees with you."

There is limited info available in that news release. I do agree that this proposed Ph3 trial smells a lot like a cardiovascular outcomes trial in high-risk patients with underlying risk factors who have contracted Covid-19. So in this regard, yes it seems quite BoM2-like. However, the news release has no mention of any patient requirement for low-HDL, renal disease/CKD, or co-administration of other drugs like SGLT2 inhibitors......all sub-group analyses in original BoM that highlighted heightened apabetalone efficacy for cardio outcomes. Additionally, the news release did not explicitly state what the primary or secondary endpoints would be in this proposed trial. Since it is a trial in Covid-19 patients, there will likely be other endpoints other than cardiovascular outcomes. The primary outcome may not even be cardiovascular related, though based on the language in the news release it sounds like cardio will be a big focus. This meeting with the FDA isn't happening until early August.....which is ~3 months away. Hopefully we won't be left completely in the dark until August......

BDAZ